Successful MHRA Inspection of Almac Group's Clinical Services UK Facility
Published: Sep 26, 2012
Commenting on the inspection, Paul O’Connor, Vice President of Quality, said:
“Once again we are extremely pleased with the outcome of our inspection. Quality is at the forefront of all our operations and all our employees continuously strive to ensure we have all the necessary processes in place to support our reputation in delivering global regulatory compliance and quality management excellence. This latest inspection is even more significant as it comes at an exciting time as we prepare to implement our new multi-million pound ERP system. This was reviewed intensively – one and a half days in total during the inspection period and resulted in no findings - testimony to our confidence that this exciting new development will further enhance our position as the premium supplier of global clinical supply chain solutions to the Pharmaceutical and Biotech industries.”
Almac has three MHRA approved clinical services facilities globally including our additional FDA assessed US facilities in Souderton, PA & Durham, NC.
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.
For more information about the Almac Group, please visit www.almacgroup.com or e-mail email@example.com
Holborn Gate, 26 Southampton Buildings
London WC2A 1BP
Telephone: +44 (0)207 861 3838
Direct: +44 (0)207 861 3019
Fax: +44 (0)207 861 3839